Timing is Critical for Effective Anti-Metastatic Immunotherapy
Author Information
Author(s): Yan Jun, Wang Zi-Yan, Yang Hong-Zhen, Liu Han-Zhi, Mi Su, Lv Xiao-Xi, Fu Xiao-Ming, Yan Hui-Min, Zhang Xiao-Wei, Zhan Qi-Min, Hu Zhuo-Wei
Primary Institution: Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Hypothesis
The timing of immunotherapy administration affects its efficacy against metastasis.
Conclusion
Prophylactic administration of the TLR4/9 agonist complex enhances anti-metastatic immunity, while therapeutic administration does not.
Supporting Evidence
- Prophylactic treatment increased survival rates and reduced metastatic nodules compared to therapeutic treatment.
- IFNγ neutralization reversed the benefits of prophylactic treatment.
- Activation of autophagy was critical for the anti-metastatic effects observed.
Takeaway
Giving cancer treatment at the right time can help stop it from spreading, but waiting too long won't work.
Methodology
Mice were injected with melanoma cells and treated with TLR4/9 agonist complex either before or after tumor cell inoculation to assess the effects on metastasis.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
Female C57BL/6 mice, aged 5-6 weeks.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website